- Reviva Pharmaceuticals Holdings Inc RVPH is trading higher with around 60k in session volume.
- Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside of around 140%.
- The company is developing its lead asset, RP5063 (brilaroxazine), to treat schizophrenia and respiratory indications.
- Analyst Jason McCarthy tells in a research note that RP5063 features a multimodal mechanism of action, which is "more completely" addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia.
- In April, RP5063 showed positive action in the schizophrenia trial that met its primary endpoint of disease severity versus placebo.
- Price Action: RVPH shares are up 9.92% at $4.21 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: BiotechLong IdeasNewsHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
